For the IS‐subtype YTN5 tumor, we applied the IL1R inhibitor and found that it can reverse the resistance of YTN5 tumors to immunotherapy, significantly enhancing the tumor‐killing effect of PD‐1 blockade (Figure 5F,G). This evidence concerns the gene PDCD1 and neoplasm.